Search research articles
Contact Us
Filters
Showing results (41-50 of 47) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 47 results.
The Journal of Clinical Investigation
|
October 2, 2014
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
Pierre-Alexandre Bart, Yunda Huang, Shelly T Karuna, et al.
JCI Insight
|
August 1, 2024
Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119
Spyros A Kalams, Barbara K Felber, James I Mullins, et al.
Plos One
|
September 21, 2018
Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial
Marnie L Elizaga, Shuying S Li, Nidhi K Kochar, et al.
The Lancet. HIV
|
May 1, 2024
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial
Ian Frank, Shuying S Li, Nicole Grunenberg, et al.
NPJ Vaccines
|
April 16, 2021
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
Kelly E Seaton, Aaron Deal, Xue Han, et al.
Science Advances
|
February 28, 2025
TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network
Taylor Jones, Junjie Feng, Olivia Luyties, et al.
Science Translational Medicine
|
July 30, 2025
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial
K Rachael Parks, Zoe Moodie, Mary A Allen, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 47) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 47 results.
The Journal of Clinical Investigation
|
October 2, 2014
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
Pierre-Alexandre Bart, Yunda Huang, Shelly T Karuna, et al.
JCI Insight
|
August 1, 2024
Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119
Spyros A Kalams, Barbara K Felber, James I Mullins, et al.
Plos One
|
September 21, 2018
Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial
Marnie L Elizaga, Shuying S Li, Nidhi K Kochar, et al.
The Lancet. HIV
|
May 1, 2024
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial
Ian Frank, Shuying S Li, Nicole Grunenberg, et al.
NPJ Vaccines
|
April 16, 2021
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
Kelly E Seaton, Aaron Deal, Xue Han, et al.
Science Advances
|
February 28, 2025
TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network
Taylor Jones, Junjie Feng, Olivia Luyties, et al.
Science Translational Medicine
|
July 30, 2025
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial
K Rachael Parks, Zoe Moodie, Mary A Allen, et al.
Page
of 5